Literature DB >> 24707235

Successful Treatment with Methylnaltrexone and IVIG for Paraneoplastic Syndrome-Associated Intestinal Pseudo-Obstruction.

Cheng Zhang1, Niravkumar J Patel2, W Carl Jacobs3, Sonal Ullman4, Tyler M Berzin2, Ram Chuttani2, Anthony J Lembo2, Jacqueline L Wolf2.   

Abstract

Entities:  

Year:  2013        PMID： 24707235      PMCID： PMC3975979     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  15 in total

Review 1.  Role of opioid ligands in the irritable bowel syndrome.

Authors:  E Corazziari
Journal:  Can J Gastroenterol       Date:  1999-03       Impact factor: 3.522

2.  Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.

Authors:  F Keime-Guibert; F Graus; A Fleury; R René; J Honnorat; P Broet; J Y Delattre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

3.  Small cell lung cancer with positive anti-Hu antibodies presenting as gastroparesis.

Authors:  David N Moskovitz; Kenneth V Robb
Journal:  Can J Gastroenterol       Date:  2002-03       Impact factor: 3.522

Review 4.  Paraneoplastic syndromes associated with anti-Hu antibodies.

Authors:  H Senties-Madrid; F Vega-Boada
Journal:  Isr Med Assoc J       Date:  2001-02       Impact factor: 0.892

5.  Immunoreactivity of Hu proteins facilitates identification of myenteric neurones in guinea-pig small intestine.

Authors:  Z Lin; N Gao; H-Z Hu; S Liu; C Gao; G Kim; J Ren; Y Xia; O C Peck; J D Wood
Journal:  Neurogastroenterol Motil       Date:  2002-04       Impact factor: 3.598

Review 6.  Autoantibody-associated sensory neuronopathy and intestinal pseudo-obstruction without detectable neoplasia.

Authors:  R S Briellmann; M Sturzenegger; H A Gerber; T Schaffner; C W Hess
Journal:  Eur Neurol       Date:  1996       Impact factor: 1.710

7.  Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation.

Authors:  David Philippe; Laurent Dubuquoy; Hervé Groux; Valérie Brun; Myriam Tran Van Chuoï-Mariot; Claire Gaveriaux-Ruff; Jean-Frédéric Colombel; Brigitte L Kieffer; Pierre Desreumaux
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

8.  Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction.

Authors:  Francisco Coret; Isabel Bosca; Loren Fratalia; Jaume Perez-Griera; Ana Pascual; Bonaventura Casanova
Journal:  J Neurooncol       Date:  2009-01-13       Impact factor: 4.130

9.  Unexplained biliary tract dilatation in lung cancer patients.

Authors:  R G Yapp; J H Siegel
Journal:  Endoscopy       Date:  1992-08       Impact factor: 10.093

Review 10.  Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.

Authors:  Andrea Kurz; Daniel I Sessler
Journal:  Drugs       Date:  2003       Impact factor: 9.546
View more
  2 in total

Review 1.  Encapsulating peritoneal sclerosis.

Authors:  Christopher J Danford; Steven C Lin; Martin P Smith; Jacqueline L Wolf
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 2.  Treatment with Methylnaltrexone and IVIG for Paraneoplastic Gastrointestinal Dysmotility.

Authors:  Madhusudan Grover; Michael Camilleri
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.